CSPC Innovation Pharmaceutical's Subsidiary Initiates Phase III Trial for SYS6043

Stock News07-16

An announcement has been made by CSPC Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) regarding its majority-owned subsidiary, CSPC Group Jushi Bio-pharmaceutical Co., Ltd. (Jushi Bio). The subsidiary has recently commenced a Phase III clinical trial for SYS6043.

The trial is designed as a randomized, multi-center, open-label study. It will evaluate SYS6043 against a chemotherapy regimen chosen by the investigator. The study participants will be individuals with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

SYS6043 is an antibody-drug conjugate (ADC) product developed by Jushi Bio that targets B7-H3. The antibody component of the drug is engineered to bind specifically to cells expressing B7-H3 on their surface, facilitating internalization into the cell.

The linker-drug component consists of a tetrapeptide linker conjugated to a topoisomerase I inhibitor. This structure is designed to be cleaved by specific proteases, which then releases the small-molecule toxin to destroy tumor cells. The drug also exhibits a bystander effect, allowing it to non-specifically eliminate surrounding tumor tissue cells.

A key feature of SYS6043 is its modified Fc region, which differs from the traditional wild-type Fc. This modification is intended to reduce uptake by lymphocytes, thereby lowering the risk of off-target toxicity and potentially enhancing the overall safety profile of the treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134407705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134407705","market":"nz","top_or_hot":-1,"title":"CSPC Innovation Pharmaceutical's Subsidiary Initiates Phase III Trial for SYS6043","media":"Stock News","content":"<p>An announcement has been made by <b>CSPC Innovation Pharmaceutical Co.,Ltd.</b> (<b>ASX: 300765</b>) regarding its majority-owned subsidiary, CSPC Group Jushi Bio-pharmaceutical Co., Ltd. (Jushi Bio). The subsidiary has recently commenced a Phase III clinical trial for SYS6043.<br><br>The trial is designed as a randomized, multi-center, open-label study. It will evaluate SYS6043 against a chemotherapy regimen chosen by the investigator. The study participants will be individuals with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.<br><br>SYS6043 is an antibody-drug conjugate (ADC) product developed by Jushi Bio that targets B7-H3. The antibody component of the drug is engineered to bind specifically to cells expressing B7-H3 on their surface, facilitating internalization into the cell.<br><br>The linker-drug component consists of a tetrapeptide linker conjugated to a topoisomerase I inhibitor. This structure is designed to be cleaved by specific proteases, which then releases the small-molecule toxin to destroy tumor cells. The drug also exhibits a bystander effect, allowing it to non-specifically eliminate surrounding tumor tissue cells.<br><br>A key feature of SYS6043 is its modified Fc region, which differs from the traditional wild-type Fc. This modification is intended to reduce uptake by lymphocytes, thereby lowering the risk of off-target toxicity and potentially enhancing the overall safety profile of the treatment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Innovation Pharmaceutical's Subsidiary Initiates Phase III Trial for SYS6043</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Innovation Pharmaceutical's Subsidiary Initiates Phase III Trial for SYS6043\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-16 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An announcement has been made by <b>CSPC Innovation Pharmaceutical Co.,Ltd.</b> (<b>ASX: 300765</b>) regarding its majority-owned subsidiary, CSPC Group Jushi Bio-pharmaceutical Co., Ltd. (Jushi Bio). The subsidiary has recently commenced a Phase III clinical trial for SYS6043.<br><br>The trial is designed as a randomized, multi-center, open-label study. It will evaluate SYS6043 against a chemotherapy regimen chosen by the investigator. The study participants will be individuals with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.<br><br>SYS6043 is an antibody-drug conjugate (ADC) product developed by Jushi Bio that targets B7-H3. The antibody component of the drug is engineered to bind specifically to cells expressing B7-H3 on their surface, facilitating internalization into the cell.<br><br>The linker-drug component consists of a tetrapeptide linker conjugated to a topoisomerase I inhibitor. This structure is designed to be cleaved by specific proteases, which then releases the small-molecule toxin to destroy tumor cells. The drug also exhibits a bystander effect, allowing it to non-specifically eliminate surrounding tumor tissue cells.<br><br>A key feature of SYS6043 is its modified Fc region, which differs from the traditional wild-type Fc. This modification is intended to reduce uptake by lymphocytes, thereby lowering the risk of off-target toxicity and potentially enhancing the overall safety profile of the treatment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMED","symbol_name":"iShares Health Innovation Active ETF","start_time":0,"source_url":"","article_id":"1134407705","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134407705","pubTimestamp":1784192793,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An announcement has been made by CSPC Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) regarding its majority-owned subsidiary, CSPC Group Jushi Bio-pharmaceutical Co., Ltd. (Jushi Bio). The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300765":"石药创新","BMED":"iShares Health Innovation Active ETF","BK0226":"食品制造","IBBQ":"Invesco Nasdaq Biotechnology ETF"},"translate_title":"石药创新药业子公司启动SYS6043 III期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1,"BMED":1,"IBBQ":1},"content_text":"An announcement has been made by CSPC Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) regarding its majority-owned subsidiary, CSPC Group Jushi Bio-pharmaceutical Co., Ltd. (Jushi Bio). The subsidiary has recently commenced a Phase III clinical trial for SYS6043.The trial is designed as a randomized, multi-center, open-label study. It will evaluate SYS6043 against a chemotherapy regimen chosen by the investigator. The study participants will be individuals with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.SYS6043 is an antibody-drug conjugate (ADC) product developed by Jushi Bio that targets B7-H3. The antibody component of the drug is engineered to bind specifically to cells expressing B7-H3 on their surface, facilitating internalization into the cell.The linker-drug component consists of a tetrapeptide linker conjugated to a topoisomerase I inhibitor. This structure is designed to be cleaved by specific proteases, which then releases the small-molecule toxin to destroy tumor cells. The drug also exhibits a bystander effect, allowing it to non-specifically eliminate surrounding tumor tissue cells.A key feature of SYS6043 is its modified Fc region, which differs from the traditional wild-type Fc. This modification is intended to reduce uptake by lymphocytes, thereby lowering the risk of off-target toxicity and potentially enhancing the overall safety profile of the treatment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134407705","isCrawlerRequest":true}